Skip to main content
. 2017 Dec 28;9(4):5216–5232. doi: 10.18632/oncotarget.23749

Figure 5. 20-223 potently inhibits cell growth in a panel of CRC cell lines.

Figure 5

(A) IC50 values from growth inhibition studies after CRC cells were treated with 20-223, AT7519 or Roscovitine for 72 hours. (B) Average IC50 values across all seven CRC cell lines after treatment with 20-223, AT7519, or Roscovitine (P < 0.001). (C) Panel containing the seven CRC cell lines used in this study and mutational status of important regulatory genes.